Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 9/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | LOX | P28300 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 3/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.37 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28895924 | 0.93 | P2RX3 (0.41) | P2RX3FFAR1LOXL2CA1CA2 | |
| SCHEMBL18249748 | 0.85 | P2RX3 (0.47) | P2RX3FFAR1LOXL2ACACBBACE1 | |
| SCHEMBL18249769 | 0.82 | CYP19A1 (0.40) | P2RX3BACE1BACE2 | |
| SCHEMBL18249838 | 0.80 | LOXL2 (0.62) | LOXL2LOX | |
| SCHEMBL2145724 | 0.80 | FFAR1 (0.47) | P2RX3FFAR1LOXL2LOX | |
| SCHEMBL20239277 | 0.80 | GRM5 (0.45) | P2RX3CA1CA2CA9CA12 | |
| SCHEMBL6183448 | 0.80 | P2RX3 (0.45) | P2RX3FFAR1LOXL2LOXACACB | |
| SCHEMBL3163471 | 0.80 | FFAR1 (0.46) | P2RX3FFAR1LOXL2LOXACACB | |
| SCHEMBL20239133 | 0.79 | KDR (0.41) | P2RX3CA1CA2CA9CA12 | |
| SCHEMBL2427347 | 0.75 | SMN1; SMN2 (0.46) | P2RX3BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3298001-B1 | DGAT2 INHIBITORS | LILLY CO ELI (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10053429-B2 | DGAT2 inhibitors | ELI LILLY AND COMPANY (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | DGAT2, DGAT1, LCAT | P2RX3 2448/4885FFAR1 113/4885LOXL2 2081/4885 |
| US-10053429-B2 | DGAT2 inhibitors | DGAT2, DGAT1, LCAT | P2RX3 1822/4885FFAR1 88/4885LOXL2 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.